185 related articles for article (PubMed ID: 23533663)
1. Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation.
Qian XL; Li YQ; Yu B; Gu F; Liu FF; Li WD; Zhang XM; Fu L
PLoS One; 2013; 8(3):e60046. PubMed ID: 23533663
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
[TBL] [Abstract][Full Text] [Related]
3. Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen.
Zhang J; Qian X; Liu F; Guo X; Gu F; Fu L
Cancer Biol Med; 2018 Feb; 15(1):29-38. PubMed ID: 29545966
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-23a inhibits melanoma cell proliferation, migration, and invasion in mice through a negative feedback regulation of sdcbp and the MAPK/ERK signaling pathway.
Lu S; Xu Q
IUBMB Life; 2019 May; 71(5):587-600. PubMed ID: 30589231
[TBL] [Abstract][Full Text] [Related]
5. Repression of miR-135b-5p promotes metastasis of early-stage breast cancer by regulating downstream target SDCBP.
Pu T; Shen M; Li S; Yang L; Gao H; Xiao L; Zhong X; Zheng H; Liu Y; Ye F; Bu H
Lab Invest; 2019 Sep; 99(9):1296-1308. PubMed ID: 31024042
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
[TBL] [Abstract][Full Text] [Related]
7. miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP.
Jana S; Sengupta S; Biswas S; Chatterjee A; Roy H; Bhattacharyya A
Biochem Biophys Res Commun; 2017 Jan; 482(1):126-133. PubMed ID: 27720715
[TBL] [Abstract][Full Text] [Related]
8. ShRNA-mediated gene silencing of MTA1 influenced on protein expression of ER alpha, MMP-9, CyclinD1 and invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and MCF-7 in vitro.
Jiang Q; Zhang H; Zhang P
J Exp Clin Cancer Res; 2011 May; 30(1):60. PubMed ID: 21595884
[TBL] [Abstract][Full Text] [Related]
9. CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.
Al-Dhaheri M; Wu J; Skliris GP; Li J; Higashimato K; Wang Y; White KP; Lambert P; Zhu Y; Murphy L; Xu W
Cancer Res; 2011 Mar; 71(6):2118-28. PubMed ID: 21282336
[TBL] [Abstract][Full Text] [Related]
10. PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3β/β-catenin/cyclin D1 signaling pathway in ER-negative breast cancer.
Gao S; Ge A; Xu S; You Z; Ning S; Zhao Y; Pang D
J Exp Clin Cancer Res; 2017 Dec; 36(1):179. PubMed ID: 29216929
[TBL] [Abstract][Full Text] [Related]
11. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks.
Banerjee S; Sengupta K; Saxena NK; Dhar K; Banerjee SK
Mol Cancer Res; 2005 Mar; 3(3):151-62. PubMed ID: 15798095
[TBL] [Abstract][Full Text] [Related]
13. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
14. miR-135a-5p and miR-124-3p Inhibit Malignancy of Glioblastoma by Downregulation of Syndecan Binding Protein.
Lin J; Wen X; Zhang X; Sun X; Yunzhi L; Peng R; Zhu M; Wang M; Zhang Y; Luo W; Luo G; Zhang Y
J Biomed Nanotechnol; 2018 Jul; 14(7):1317-1329. PubMed ID: 29944105
[TBL] [Abstract][Full Text] [Related]
15. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
[TBL] [Abstract][Full Text] [Related]
16. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.
Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J
Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353
[TBL] [Abstract][Full Text] [Related]
17. Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.
Gangemi R; Mirisola V; Barisione G; Fabbi M; Brizzolara A; Lanza F; Mosci C; Salvi S; Gualco M; Truini M; Angelini G; Boccardo S; Cilli M; Airoldi I; Queirolo P; Jager MJ; Daga A; Pfeffer U; Ferrini S
PLoS One; 2012; 7(1):e29989. PubMed ID: 22267972
[TBL] [Abstract][Full Text] [Related]
18. Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.
Syed Khaja AS; Dizeyi N; Kopparapu PK; Anagnostaki L; Härkönen P; Persson JL
PLoS One; 2013; 8(8):e72210. PubMed ID: 23991063
[TBL] [Abstract][Full Text] [Related]
19. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation.
Liu J; Bai W; Zhou T; Xie Y; Yang B; Sun J; Wang Y; Li X; Hou X; Liu Z; Fu D; Yan J; Jiang W; Zhao K; Zhou B; Yuan S; Guo Y; Wang H; Chang A; Gao S; Shi L; Huang C; Yang S; Hao J
Gut; 2023 Sep; 72(9):1722-1737. PubMed ID: 36828627
[TBL] [Abstract][Full Text] [Related]
20. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
